Metronome LLC v. Global Products Group LLC — Cannabis Topical Patent Dispute
Metronome LLC filed suit in the New Jersey District Court against Global Products Group LLC, asserting infringement of US9095563B2, a patent covering topical treatments incorporating Cannabis sp. derived botanical drug products. The case closed after 163 days via voluntary dismissal before the defendant had answered — leaving the dispute unresolved on the merits.
Cannabis topical patent suit exits before defendant responds
On 18 March 2025, Metronome LLC filed a patent infringement action in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-01935) against Global Products Group LLC. The sole asserted patent, US9095563B2 (application no. US14/498555), covers topical treatments incorporating Cannabis sp. derived botanical drug products — a technology domain attracting growing commercial and regulatory attention as cannabis-derived therapeutics expand into mainstream consumer and pharmaceutical markets.
The case closed on 28 August 2025 after Metronome filed a notice of voluntary dismissal pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). That rule permits a plaintiff to dismiss an action without a court order provided the defendant has not yet served an answer or a motion for summary judgment — both of which are confirmed absent here. The public record does not explicitly adjudicate with-prejudice or without-prejudice status beyond the filing of the notice itself; see Card 2 for the legal distinction and its practical consequences.
At 163 days, the case resolved relatively quickly for district court patent litigation, and entirely before substantive engagement by the defendant. This pattern is consistent with several scenarios: a licensing agreement reached privately, a strategic decision to refile in a different forum, or a reassessment of claim strength following further pre-litigation diligence. None of these can be confirmed from the public record. Plaintiff’s counsel, Antranig Niaz Garibian of Garibian Law Offices PC, filed the dismissal; no defendant counsel of record is listed.
Filing to Voluntary dismissal in 163 days
163 days — resolved before defendant’s answer, suggesting early-stage exit
Voluntarily dismissed: what Rule 41(a)(1)(A)(i) means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s unilateral right to exit
Federal Rule of Civil Procedure 41(a)(1)(A)(i) allows a plaintiff to dismiss an action as of right — with no court order required — provided the defendant has not yet answered or moved for summary judgment. That condition is confirmed here. The dismissal takes effect upon filing of the notice, making it one of the cleanest procedural exits available in U.S. federal civil litigation. No merits ruling was issued and the court made no substantive findings on infringement or validity.
Rule 41(a)(1)(A)(i) — no court order neededPublic record is silent on prejudice status — the distinction matters
A dismissal ‘with prejudice’ permanently bars re-filing the same claims. A dismissal ‘without prejudice’ preserves the right to refile. Under Rule 41(a)(1)(A)(i), dismissals are without prejudice by default unless the notice expressly states otherwise — but practitioners should verify the actual notice text. The verdict text here states ‘without prejudice.’ This means Metronome LLC likely retains the right to re-assert US9095563B2 against Global Products Group LLC in future proceedings, subject to applicable statutes of limitations.
Without prejudice — refiling possibleGlobal Products Group exits without admitting liability
Because the case terminated before Global Products Group LLC filed any responsive pleading, the defendant made no admissions and no infringement finding was entered against it. However, the without-prejudice dismissal means the threat has not been extinguished. Global Products Group should consider whether its cannabis topical product lines remain exposed to future assertion of US9095563B2, and whether proactive steps — such as an FTO analysis or a declaratory judgment action — are warranted.
No liability found — exposure remainsCannabis topical IP remains live: sector should monitor US9095563B2
The voluntary dismissal without prejudice leaves US9095563B2 fully enforceable. For companies commercialising topical products incorporating Cannabis sp. derived botanical drug products, the patent remains a live clearance risk. The early exit — before any claim construction, IPR filing, or invalidity defence — means no narrowing interpretation of the patent’s claims has been established. This typically increases uncertainty for third parties operating in adjacent product spaces and signals that the patentee may revisit enforcement.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | METRONOME LLC | Company | Cannabis-derived topical therapeutics IP holder — holder of US9095563B2Search in Eureka ↗ |
| Defendant | GLOBAL PRODUCTS GROUP LLC | Company | Global Products Group LLC — defendant in cannabis topical treatment infringement actionSearch in Eureka ↗ |
| Plaintiff counsel | Antranig Niaz Garibian | Attorney | Counsel for METRONOME LLCSearch in Eureka ↗ |
| Plaintiff law firm | Garibian Law Offices, PC | Law Firm | Representing METRONOME LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal was filed by plaintiff Metronome LLC under Rule 41(a)(1)(A)(i), which requires no court order and takes effect automatically upon filing. The notice expressly states dismissal ‘without prejudice,’ confirming that no final judgment on the merits was entered. No infringement finding, invalidity ruling, or claim construction has been issued. The without-prejudice designation is legally significant: it preserves Metronome’s right to reassert the same claims against Global Products Group LLC in a future action, subject to the six-year damages limitation period under 35 U.S.C. § 286.
US9095563B2 — Cannabis sp. derived topical botanical drug product
US9095563B2 (application no. US14/498555) protects topical treatments incorporating Cannabis sp. derived botanical drug products. The patent sits at the intersection of pharmaceutical formulation and botanical drug regulation — a space where FDA’s botanical drug guidance and state cannabis law create a complex clearance environment. The application number sequence suggests a mid-2010s filing timeline, consistent with early commercial and therapeutic interest in cannabinoid-based topical formulations ahead of the broader CBD market expansion.
As the cannabis-derived topical market has grown into a multi-billion dollar segment spanning OTC skincare, pharmaceutical analgesics, and therapeutic dermatology, patents covering formulation and drug delivery in this space carry significant strategic value. US9095563B2 represents a potential blocking position for competitors developing similar cannabis-derived topical products. The fact that it has not been subjected to IPR or claim construction proceedings means its full scope — and vulnerability — remains commercially uncertain, raising the stakes for any FTO clearance exercise in this domain.
Should you run an FTO analysis against US9095563B2?
Any company developing, manufacturing, or distributing topical products that incorporate Cannabis sp. derived botanical drug ingredients should treat US9095563B2 as a live clearance risk. This case confirms the patent is being actively asserted. The without-prejudice dismissal means enforcement could resume against the same defendant or be extended to others. R&D teams formulating cannabis-derived topicals — whether for OTC, cosmeceutical, or prescription channels — should evaluate whether their product design, extraction method, or formulation approach intersects with the patent’s claims.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US9095563B2 against your product specifications, identify relevant prior art that could support invalidity arguments, and surface related patents in the cannabis topical formulation space that may represent additional risk or design-around opportunities. Given the absence of any judicial claim construction, Eureka’s AI-assisted analysis can help frame the interpretive range of the claims and flag where your product profile creates the greatest overlap — before litigation risk materialises.
Run a freedom-to-operate analysis on US9095563B2 to assess your product’s exposure
Run FTO in Eureka →Similar cannabis-derived pharmaceutical patent cases in U.S. district courts
Cases involving cannabis-derived botanical drug product patents litigated in U.S. district courts, including comparable Rule 41 dismissals and pharmaceutical formulation infringement actions.
What this case signals for the cannabis-derived therapeutics IP landscape
A Rule 41 exit before the defendant answers is rarely the end of the story — especially in a fast-moving sector like cannabis topical therapeutics.
Early dismissals in cannabis IP often precede licensing negotiations or refiling
When a plaintiff voluntarily dismisses before the defendant answers, it frequently suggests a private resolution is in progress or that the plaintiff is reassessing litigation strategy. In the cannabis-derived therapeutics sector — where IP portfolios are still maturing and licensing infrastructure is developing — this pattern is consistent with a pivot to licensing discussions rather than a concession of weakness.
US9095563B2 has not faced claim construction — scope remains undefined
No Markman hearing, IPR petition, or invalidity challenge has been litigated to a ruling in this case. That means the claim scope of US9095563B2 covering cannabis-derived topical treatments is judicially undefined. For competitors in the cannabis topical space, this heightens FTO uncertainty — the patent’s boundaries have not been tested by an adversarial proceeding.
METRONOME v GLOBAL — key questions answered
Metronome LLC filed a patent infringement suit in the District of New Jersey on 18 March 2025 asserting US9095563B2, covering cannabis-derived topical treatments. The case was voluntarily dismissed by Metronome on 28 August 2025 under Rule 41(a)(1)(A)(i), before the defendant filed any answer. The dismissal was without prejudice, meaning no merits ruling was issued and Metronome retains the right to refile.
US9095563B2 protects topical treatments incorporating Cannabis sp. derived botanical drug products. It is relevant to any company formulating, selling, or distributing cannabis-derived topical products — including CBD-based skincare, analgesic patches, and therapeutic dermatology applications. Active enforcement of the patent in federal court signals patentee intent, and the absence of any claim construction ruling means the scope remains broadly uncertain.
Rule 41(a)(1)(A)(i) allows a plaintiff to unilaterally dismiss a lawsuit without court approval, provided the defendant has not yet answered or moved for summary judgment. No liability finding is entered against the defendant. However, if the dismissal is without prejudice — as appears to be the case here — the plaintiff may refile the same claims in the future, meaning the defendant’s exposure to the asserted patent is not extinguished.
Based on the available record, the dismissal was without prejudice, which typically preserves the plaintiff’s right to refile. However, any refiled action would be subject to the six-year damages limitation period under 35 U.S.C. § 286 and any applicable statutes of limitations. The public record does not disclose any settlement agreement or covenant not to sue that would bar future litigation.
Companies operating in the cannabis-derived topical product space should conduct an FTO analysis against US9095563B2, as the patent remains fully enforceable following the without-prejudice dismissal. No claim construction or invalidity ruling was issued, leaving the claim scope judicially undefined. Monitoring Metronome LLC’s enforcement activity and any future filings in the District of New Jersey or other forums is also advisable for competitors in this product category.
PatSnap Eureka searches patents and litigation data to answer instantly.